Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT04935853
Recruiting Observational

Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study

NCT04935853 · tracked via the Priya Life Science France tracker
Sponsor
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase
Observational
Started
2022-05-23
Last updated
2025-07-23

Condition(s) studied

Biliary Tract Cancer

Study summary

The objective of this study is to identify prognosis and predictive markers of response to treatments (surgery, chemotherapy, targeted therapy,loco-regional treatments ) in patients with bile duct cancer. The effectiveness and tolerance of these treatments in current practice will also be evaluated.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * All locations of primitives (intrahepatic CCA, extrahepatic CCA, adenocarcinoma of the gallbladder; ampullomas excluded) * Age \> 18 years * Diagnosed between 2003 and 2030 (minimum follow-up 2 years) * Written written non-opposition +/- signed informed consent for genetic studies (N.B.: exemption requested for a deceased patient) N.B. Authorized inclusion in a therapeutic research protocol Exclusion Criteria: * Patient under guardianship, curatorship or legal protection * Pregnant or breastfeeding women * Any medical, psychological or social situation, which could prevent the compliance with the protocol according to the investigator's assessment * Refusal to participate in the study

Primary outcome measure(s)

  • Rate of patients with advanced bile duct cancer (BDC) experiencing overall survival (OS) less than 6 months — Up to 10 years from the date of initial cancer diagnosis (or until death if it occurs before 10 years)
    Identification of clinical and tumor predictive factors of overall survival (OS) (prognostic markers) in patients with advanced bile duct cancer (BDC). OS defined as a period between the start of treatment and death, whatever the cause.

Trial sites (32)

FacilityCityRegionStatus
CHU Hôpital Sud Amiens Amiens France Recruiting
CHU Angers Angers France Recruiting
CHU Besançon Besançon France Recruiting
Hôpital Avicenne Bobigny France Recruiting
CHU - Henri Mondor Créteil France Recruiting
CHU Dijon Dijon France Recruiting
CHU Grenoble Grenoble France Recruiting
CHU Lille Lille France Recruiting
Centre Léon Bérard Lyon France Recruiting
Hôpital Croix Rousse Lyon France Recruiting
Hôpital Edouard Herriot Lyon France Recruiting
Hôpital Privé Jean Mermoz Lyon France Recruiting
Institut Paoli Calmette Marseille France Recruiting
CHU Saint Eloi Montpellier Montpellier France Recruiting
CHR Orléans Orléans France Recruiting
Groupe Hospitalier Pitié Salpêtrière Paris France Recruiting
Hôpital Ambroise Paré Paris France Recruiting
Hôpital Cochin Paris France Recruiting
Hôpital Saint Antoine Paris France Recruiting
Hôpital Saint Louis Paris France Recruiting
Institut Mutualiste Montsouris Paris France Recruiting
Hôpital Haut Lévêque Pessac France Recruiting
CHU Poitiers Potiers France Recruiting
Hôpital Robert Debré -CHU Reims Reims France Recruiting
Centre Eugène Marquis Rennes France Recruiting
CHU Rouen Charles Nicolle Rouen France Recruiting
Institut Curie Saint-Cloud France Recruiting
CHU Saint Etienne Saint-Etienne France Recruiting
CHU Rangueil Toulouse France Recruiting
CHU Tours Tours France Recruiting
CHRU Nancy Site Brabois Vandœuvre-lès-Nancy France Recruiting
Institut Gustave Roussy Villejuif France Recruiting

More GERCOR - Multidisciplinary Oncology Cooperative Group trials in France

Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC Recruiting
Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy. Active, not recruiting
Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas Recruiting
QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters. Active, not recruiting
iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab Active, not recruiting

Other trials for the same condition

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) Recruiting
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) Active, not recruiting
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer Recruiting
Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients Recruiting
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04935853 on ClinicalTrials.gov ↗ ← All trials in France